Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Holding GB:GSK?
Track your performance easily
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,371.40p - 1,823.50p
Previous Close1,476p
Volume933.66K
Average Volume (3M)7.56M
Market Cap
£60.21B
Enterprise Value72.49B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)14.9
Beta0.55
Next Earnings
Oct 30, 2024EPS Estimate
£0.44Last Dividend Ex-Date
Aug 15, 2024Dividend Yield4.07%
Share Statistics
EPS (TTM)0.99
Shares Outstanding4,145,087,815
10 Day Avg. Volume8,897,363
30 Day Avg. Volume7,562,718
Standard Deviation0.07
R-Squared0.13
Alpha-0.00133
Financial Highlights & Ratios
Price to Book (P/B)425.36
Price to Sales (P/S)1.95
Price to Cash Flow (P/CF)14.80
P/FCF Ratio23.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,708.00pPrice Target Upside17.37% Upside
Rating ConsensusHold
Number of Analyst Covering12
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessGSK announced its Nucala COPD PIII trial (MATINEE) has met its primary endpoint, showing a clinically meaningful and statistically significant reduction in exacerbations compared to placebo.
Legal SettlementGSK settles 93% of Zantac cases for up to $2.2bn, significantly lower than the worst-case scenario, likely removing Zantac risk from the share price.
Product RolloutShingrix confirmed broader European rollout progressing well with France the next big opportunity.
Bears Say
Litigation RisksThe persistence of Zantac overhang poses a significant risk until the outcome of the appeal, with potential for unpredictable jury trials awarding substantial damages unless a successful appeal or settlement occurs.
Market CompetitionGSK's market share in the US for RSV is expected to continue declining due to contracting dynamics, which signifies increased competition and pressure on their market positioning.
Product PerformanceArexvy's sales performance has shown significant weakness, with actual figures falling well below consensus estimates, raising concerns about its future growth potential.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
11.28% Mutual Funds
0.09% Other Institutional Investors
76.68% Public Companies and
Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1371.40p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 30, 2024 which is in 8 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 31, 2024. The company reported 0.434p earnings per share for the quarter, beating the consensus estimate of 0.382p by 0.052p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15p which represents an annual dividend yield of 4.07%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.44.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,088,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.434p in its last earnings report, beating expectations of 0.382p. Following the earnings report the stock price went down -1.978%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
1,708.00p (17.37% Upside)
1,708.00p (17.37% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.96%
12-Months-Change
Fundamentals
Return on Equity
29.80%
Trailing 12-Months
Asset Growth
-2.35%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,708.00p
▲(17.37% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
22/38 ratings generated profit
1 Year Average Return
+3.80%
reiterated a buy rating 14 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +3.80% per trade.
---